4.5 Article

Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies

Journal

AMERICAN HEART JOURNAL
Volume 159, Issue 5, Pages 864-870

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.ahj.2010.02.006

Keywords

-

Funding

  1. NHLBI NIH HHS [N01HC75150, N01HC55019, N01 HC055015, N01HC55016, U01 HL080295-05, N01 HC055020, N01 HC055021, N01HC55018, N01 HC015103, N01 HC055022, N01HC55222, N01 HC045133, N01 HC085079, N01 HC055019, N01 HC075150, U01 HL080295, N01 HC055016, N01HC85086, N01HC55021, N01 HC055018, N01HC55022, N01HC55020, N01HC55015, N01 HC055222, N01 HC085086, N01 HC035129, N01HC85079] Funding Source: Medline
  2. NIA NIH HHS [R01 AG018915, R01 AG019259-07, R37 AG018915, R01 AG019259] Funding Source: Medline

Ask authors/readers for more resources

Background Many African Americans carry an amyloidogenic transthyretin mutation (TTR V122I), with a high risk for cardiac TTR amyloid deposition after the age of 65 years. We wished to determine the allele frequency and its clinical penetrance in community-dwelling African Americans. Methods Five thousand consenting African Americans, aged 41 to 93 years, in 2 community studies of cardiovascular risk (CHS and ARIC) were included in the study. The following were performed: genotyping of banked DNA for TTR V122I allele status and review of cardiovascular and demographic parameters in CHS and ARIC databases, with statistical comparisons of the frequency of congestive heart failure, survival, and occurrence of features of cardiac amyloidosis in carriers of the amyloidogenic allele and controls. Results One hundred nineteen (3.23%) of 3,712 ARIC and 17 (2.12%) of 805 CHS African Americans carried TTR V122I. After the age of 65 years (CHS), the frequencies of congestive heart failure (38% vs 15%, relative risk 2.62, P = .04) and mortality (76% vs 53%, relative risk 1.46, P = .08) were higher in V122I allele carriers than in age-, gender-and ethnically matched controls. In ARIC (all subjects <65 years old), there were no differences between carriers and noncarriers in mortality, frequency of congestive heart failure, or findings consistent with cardiac amyloidosis. Conclusions Heterozygosity for the amyloidogenic TTR V122I mutation is relatively common in community-dwelling African Americans. Before the age of 65 years, the allele has no discernible impact on cardiac function or mortality. After the age of 70 years, carriers show a higher frequency of congestive failure and greater mortality with more echocardiographic evidence suggestive of cardiac amyloidosis, findings consistent with age-dependent clinical penetrance of this autosomal dominant gene. (Am Heart J 2010; 159: 864-70.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available